Rethinking the appraisal and approval of drugs for type 2 diabetes

Naci, Huseyin, Lehman, Richard, Wouters, Olivier J., Goldacre, Ben and Yudkin, John S (2015) Rethinking the appraisal and approval of drugs for type 2 diabetes. BMJ, 351 (h5260). ISSN 1756-1833

Preview

PDF - Accepted Version Download (539Kb) | Preview

• LSE expert's profile
• LSE expert's profile

• Published item via DOI

Abstract

The process for approving new drugs for type 2 diabetes illustrates the significant shortcomings of the regulatory standards for licensing, reimbursing, and adopting new drugs. Regulatory reform is needed to improve the real-world therapeutic value of anti-diabetic drugs.

Item Type:	Article
Official URL:	http://www.bmj.com/
Additional Information:	© 2015 BMJ Publishing Group Ltd
Library of Congress subject classification:	R Medicine > RA Public aspects of medicine
Sets:	Research centres and groups > LSE Health and Social Care Research centres and groups > LSE Health
Date Deposited:	22 Oct 2015 14:03
URL:	http://eprints.lse.ac.uk/64115/

Actions (login required)

Record administration - authorised staff only